AbbVie Inc (ABBV)vsScworx Corp (WORX)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
WORX
Scworx Corp
$0.46
+0.04%
HEALTHCARE · Cap: $543,980
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2125282% more annual revenue ($61.16B vs $2.88M). ABBV leads profitability with a 6.9% profit margin vs -154.4%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
WORX
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Intrinsic value data unavailable for WORX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -76.3% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : WORX
The strongest argument for WORX centers on Price/Book, Debt/Equity. Revenue growth of 13.8% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : WORX
The primary concerns for WORX are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while WORX is a turnaround play — different risk/reward profiles.
WORX carries more volatility with a beta of 2.26 — expect wider price swings.
WORX is growing revenue faster at 13.8% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 37/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Scworx Corp
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Scworx Corp (WORX) stands at the forefront of healthcare data solutions, dedicated to optimizing clinical data management for healthcare providers and stakeholders. Utilizing cutting-edge technology, the company enhances operational efficiency and bolsters the quality of care through robust analytics, empowering institutions to make informed, data-driven decisions. With a strategic focus on scalability and innovation, Scworx is well-positioned to meet the growing demand for data-centric solutions in the healthcare sector, thereby improving patient outcomes and enabling effective cost management. This commitment to transforming healthcare delivery solidifies Scworx's critical role in the rapidly evolving healthcare landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?